Systemic atrophies primarily affecting central nervous system in diseases classified elsewhere (G13) ICD-10-CM
The G13 code range covers systemic atrophies primarily affecting central nervous system in diseases classified elsewhere with 5 ICD-10-CM diagnosis codes. 4 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Codes in the G13 Range 5 codes · 4 billable
- G13 Systemic atrophies primarily affecting central nervous system in diseases classified elsewhereNon-billable
- G13.0 Paraneoplastic neuromyopathy and neuropathy
- G13.1 Other systemic atrophy primarily affecting central nervous system in neoplastic disease
- G13.2 Systemic atrophy primarily affecting the central nervous system in myxedema
- G13.8 Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere
About the G13 Code Range
These conditions involve atrophy, or tissue wasting, that primarily affects the central nervous system in diseases classified elsewhere.
The subdivisions distinguish G13.0 for paraneoplastic nerve and muscle conditions, and G13.1 for other central nervous system atrophy in neoplastic disease. G13.2 identifies atrophy in myxedema, while G13.8 identifies atrophy in other diseases classified elsewhere.
Questions About This Page
How many billable codes are in the G13 range?
Of the 5 codes in this range, 4 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the G13 range classify?
The range classifies systemic atrophies primarily affecting central nervous system in diseases classified elsewhere. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
